ClinicalTrials.gg
Sign In

Glomerulosclerosis, Focal Segmental clinical trials

The registry lists 105 studies for Glomerulosclerosis, Focal Segmental across more than 10 countries. 33 are recruiting or about to start. 60 of them are mainly about Glomerulosclerosis, Focal Segmental (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Glomerulosclerosis, Focal Segmental studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
50
Recruiting
30
Terminated
10
Status unknown
4
Active, not recruiting
4
Withdrawn
4

Phase

Phase 2
37
Phase 1
16
Phase 3
11
Phase 4
5
Early Phase 1
1

Where

United States
68
United Kingdom
13
Italy
13
Canada
12
China
12
Germany
12

Who runs them

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (11) · Travere Therapeutics, Inc. (6) · Northwell Health (6) · University of Michigan (5) · Goldfinch Bio, Inc. (3) · Vertex Pharmaceuticals Incorporated (3) · Amgen (2) · Istanbul University (2)

What is being tested here

Drugs under test in Glomerulosclerosis, Focal Segmental studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Sparsentan115
Propagermanium112
Sibeprenlimab101
Praliciguat101
BI-764198111
N-acetylmannosamine101
Frexalimab101
Brivekimig101
Rilzabrutinib101
BAT4406F111

Drug classes tested here Angiotensin receptor blockers (ARBs) 1 open · Endothelin receptor antagonists 1 open · Corticosteroids 5 · Calcineurin inhibitors 3

Coming up

4phase 3 studies under way
11studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 30 Glomerulosclerosis, Focal Segmental studies recruiting now, 11 (37%) set no upper age limit and 12 (40%) stop at 75 or younger. 22 (73%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (7%) take healthy volunteers.

Recruiting studies that take each age, of 30
AgeWomenMen
1018 (60%)18 (60%)
1827 (90%)27 (90%)
3024 (80%)24 (80%)
4024 (80%)24 (80%)
5023 (77%)23 (77%)
6523 (77%)23 (77%)
7523 (77%)23 (77%)
8514 (47%)14 (47%)

Across all 105 studies, recruiting or not: 46% stop at 75 or younger and 30% at 65; 52% take children; 0% are for women only and 0% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Glomerulosclerosis, Focal Segmental studies take

Of 17 phase 2 interventional studies under Glomerulosclerosis, Focal Segmental, half reached primary completion within 35 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 235 mo21–42 · 17 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 105. Browse all 105 → or search them.